Project Grant R01HL173868
- This federal Project Grant award of $429,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a study to investigate the impact of selective vagal neuromodulation on heart failure indices. The 2-year project, with a start date of September 1, 2025, will be conducted by the University of Colorado-Denver. The research aims to better understand the neural interface by studying the effects of selective activation of cholinergic (efferent)...
- The federal Project Grant award of $726,452 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to model intra- and inter-cellular networks involved in TRPC6-dependent cardiac fibrosis. The award aims to leverage computational methods and multi-scale experiments to better understand how TRPC6 signaling drives myofibroblast transformation and fibrosis in response to cardiac and dermal wounds. The research will be conducted by the...
- The University of South Florida was awarded a $2,074,842 Project Grant by the National Heart, Lung, and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) to investigate how post-translational modifications of the CaMKII protein during chronic diabetes impact endothelial small-conductance calcium-activated potassium (SK) channel activity, coronary microvascular function, and myocardial blood flow. The overall goal is to expand scientific understanding of the mechanisms underlying...
- This federal Project Grant award, valued at $765,288.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The funding supports research at the University of California, San Diego (UCSD) to investigate the biological mechanisms of the infarct borderzone - the complex and dynamic region between areas of cell death and normal tissue in the heart following a myocardial infarction. The research aims to advance...
- This federal Project Grant award of $169,020.00 was provided by the National Heart Lung and Blood Institute (NHLBI), which operates under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pennsylvania investigating the impact of obesity and diabetes on coronary microvascular defects in heart failure with preserved ejection fraction (HFpEF). The research will use an animal model of HFpEF to compare the temporal progression...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...
- The University of Florida received a $149,348 Project Grant from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to conduct research on the cellular mechanisms of acute-intermittent hypercapnic-hypoxia induced phrenic motor plasticity. The project will monitor phrenic nerve activity in anesthetized rats as a proxy for respiratory motor output, with the goal of enhancing understanding of the pathways involved in phrenic long-term facilitation (PLTF)...
- The University of Alabama at Birmingham (UAB) received a $637,732 project grant from the National Heart, Lung, and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on improving the cardiac microenvironment as a novel strategy against diabetic ischemic heart failure. The project aims to leverage insights from cellular secretome research to transform treatment strategies for diabetic ischemic heart failure. Specifically, the research will investigate how...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to elucidate the ionic and molecular mechanisms underlying the regulation and dysregulation of visceral nociceptor excitability. Specifically, the research aims to investigate the role of the Kv7/M-type (IM) and Kv1/D-type (ID) potassium channels in modulating the excitability of vagal visceral nociceptors. The goal is to identify novel...
- This Project Grant award of $249,000.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), will fund research to investigate the calcium-dependent autoregulation of vasopressin neurons in a rodent model of heart failure. The key objectives are to test the hypothesis that impaired intracellular calcium signaling and somatodendritic release of vasopressin lead to the hyperexcitability and excess peripheral vasopressin...
This federal Project Grant award for $726,035.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to map the vagal and spinal afferent innervation of healthy and diabetic rat hearts, as well as adapt these techniques to study diabetes-induced remodeling of nociceptive afferent innervation in human hearts. The primary objectives are to better understand the structural and functional roles of these cardiac afferent nerves, including associating specific afferent systems with their innervated regions, fiber types, neurochemical phenotypes, and sensory modalities. This knowledge could inform future strategies to selectively modulate cardiac afferent activity for therapeutic benefit in cardiovascular disease. The project is being conducted by the University of Central Florida, a prominent public research institution, over the period from September 2025 to June 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $726.0k | 9/11/25 |